abstract |
Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), and medically refractory ulcerative colitis (MR-UC). In particular, anti-TL1A antibodies useful in the treatment of IBD are disclosed. |